Abstracts tagged "DMARDs"

Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…
Abstract Number: 137 • 2016 ACR/ARHP Annual Meeting
Imaging Remission By Musculoskeletal Ultrasound Leads to a Better Functional Outcome – Results of the US Impera Study – US 7-Score Implementation Study in Early Rheumatoid Arthritis
Anne-Marie Glimm¹, Sarah Ohrndorf², Imma Fischer³, Johannes Strunk⁴, Wolfgang A. Schmidt⁵, Wolfgang Hartung⁶, Herbert Kellner⁷, Horst Sattler⁸, Gabriela Schmittat¹, GR Burmester⁹ and Marina Backhaus¹⁰, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Biostatistik Tuebingen, Tuebingen, Germany, ⁴Department of Rheumatology, Hospital 'Porz am Rhein', Academic Hospital of the University of Cologne, Cologne, Germany, ⁵Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Asklepios Klinik Bad Abbach, Bad Abbach, Germany, ⁷Department of Internal Medicine – Rheumatologic Day Clinic, Krankenhaus Neuwittelsbach, Academic Hospital of Ludwig-Maximilians-University Munich, Munich, Germany, ⁸Internal Medicine and Rheumatology Practice, Bad Duerkheim, Bad Duerkheim, Germany, ⁹Charité – University Medicine Berlin, Berlin, Germany, ¹⁰Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany
Background/Purpose: Novel treat-to-target strategies present new challenges to treatment monitoring in rheumatoid arthritis (RA). To compare functional outcomes in early RA patients monitored by standard…
Abstract Number: 1981 • 2016 ACR/ARHP Annual Meeting
A Pilot Pulsed Arterial Spin Labeling Study of Regional Cerebral Blood Flow in Response to Pain in RA, before and after DMARD Treatment
Yvonne C. Lee¹, Alexander Fine², Ekaterina Protsenko³, Elena Massarotti⁴, Robert R. Edwards⁵, Vitaly Napadow⁶ and Marco Loggia³, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, ⁶Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Although significant advances have been made in treating inflammation in RA, little is known about central nervous system (CNS) pain pathways in inflammatory arthritis.…
Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Ozge Kockara¹, Merve Sibel Gungoren², Erdem Karabulut³, Sebnem Ataman⁴ and Filiz Akbiyik², ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…
Abstract Number: 566 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Ability to Accurately Recall DMARD Information Immediately Following an Office Visit with Their Rheumatologist
Delesha Carpenter¹, Lorie Geryk², Courtney Roberts², Beth L. Jonas³ and Susan J. Blalock⁴, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³Thurston Arthritis Research Ct, University of North Carolina Thruston Arthritis Research Center, Chapel Hill, NC, ⁴Eshelman School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC
Background/Purpose: Patient misunderstandings about DMARDs may contribute to nonadherence. We present longitudinal observational data regarding whether patients can accurately recall medication information about a newly-prescribed…
Abstract Number: 1991 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis
Gulsen Ozen^1,2, Sofia Pedro³, Marie Holmqvist⁴, Frederick Wolfe³ and Kaleb Michaud^2,3, ¹Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Diabetes mellitus (DM) is an important cardiovascular risk factor in RA. Although a few prior studies reported DM risk reduction with hydroxychloroquine (HCQ) and…
Abstract Number: 2607 • 2016 ACR/ARHP Annual Meeting
Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy
Tate Johnson¹, Ted R Mikuls², Harlan Sayles¹, Michael J. Duryee³, Geoffrey M. Thiele¹, Mary Brophy^4,5 and James R. O'Dell⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁶Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease is a significant comorbidity among RA patients. As such, dyslipidemia and the effect of DMARD therapy on lipid profiles is an important…
Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting
The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)
Sonia Lagacé¹, Louis Bessette^2,3, Louis Coupal⁴ and Denis Choquette⁴, ¹Medicine, Laval University, Quebec, QC, Canada, ²Rheumatology, Laval University, Québec, QC, Canada, ³Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Machaon Bonafede¹, Wenhui Wei², Chieh-I Chen³, Donna McMorrow¹, Stefano Fiore⁴, Jonathan Fay³, Toshio Kimura³ and Jeffrey R. Curtis⁵, ¹Truven Health Analytics, Cambridge, MA, ²Sanofi US, Inc., Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgwater, NJ, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…
Abstract Number: 2624 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies Titers Are Independently Modulated By Disease Activity and Synthetic or Biologic Dmards in a Seropositive Early Arthritis Population
Elena García Lorenzo¹, Daniel Useros², Aranzazu Alfranca³, Ana M. Ortiz Garcia¹, Pablo Moreno Fresneda¹, Isidoro Gonzalez-Alvaro¹ and Rosario García-Vicuña¹, ¹Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ²Rheumathology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ³Immunology, Immunology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Early introduction of some biologic (b) DMARDs has been proposed to reduce anti-citrullinated protein antibodies (ACPA) titers in clinical trials settings. However, less information…
Abstract Number: 611 • 2016 ACR/ARHP Annual Meeting
Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs
Hendrik Schulze-Koops¹, Jürgen Wollenhaupt², Marita Winnemöller³, Ines Klaudius³ and Helena Löffler³, ¹Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ³Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In previous clinical studies the human monoclonal TNFα-antibody golimumab (GLM) showed a good clinical response and a favorable benefit:risk profile in the treatment of…
Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting
Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Hsin-Hsuan Juo^1,2, Anders Peck^3,4, Nancy Gove⁵ and Bernard Ng^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ³Medicine / Rheumatology, University of Washington, Seattle, WA, ⁴The Seattle Arthritis Clinic, Seattle, WA, ⁵Biostatistics, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…
Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…
Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre-Gallego¹, Mariana Marco-Mingot³, Ana Pons¹, Xavier Barber⁴, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Juan Molina³, Marina Sanchís⁴, Mario García-Carrasco⁵ and AIRE-MB Group, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴CIO, Universidad Miguel Hernández, Elche, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
Abstract Number: 2081 • 2016 ACR/ARHP Annual Meeting
Dermal Temperature Is an Excelent Prognostic Indicator to Guide RA Therapy
JoAnn Ball¹ and Maria Greenwald², ¹rheumatology, Desert Medical Advances, Palm Deseret, CA, ²Rheumatology, Desert Medical Advances, Palm Desert, CA
Background/Purpose: Nurses and rheumatology extenders can rapidly identify rheumatoid arthritis (RA) patients who flare, with high predictive value for which individual is at high risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.